Single answer
Is Aldeyra Therapeutics Inc (ALDX) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Aldeyra Therapeutics Inc is $7.00, which is $1.510 (27.50%) above the current price today's price.
Low target: $7.00 | High target: $7.00
Latest analyst updates
Recent rating and price target changes for this stock.
Company snapshot
A quick overview of the business and its public profile.
Aldeyra Therapeutics Inc a biotechnology company develops and commercializes medicines for immunemediated ocular and systemic diseases The companys lead product candidate is reproxalap a reactive aldehyde species RASPmodulator which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis It also develops ADX629 a firstinclass orally administered RASP modulator that is Phase II clinical trial for psoriasis asthma and COVID19 and ADX2191 a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy and phase II clinical trial for the treatment of retinitis pigmentosa as well as for treating primary vitreoretinal lymphoma The company has a license agreement with Madrigal Pharmaceuticals Inc for developing ADX1612 which inhibits the protein chaperome for the treatment of inflammatory diseases The company was formerly known as Aldexa Therapeutics Inc and changed its name to Aldeyra Therapeutics Inc in March 2014 Aldeyra Therapeutics Inc was incorporated in 2004 and is based in Lexington Massachusetts
Website: https://www.aldeyra.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.20. Cash flow to debt ratio: -2.58. Net profit margin: 0.00%. Inflation risk score: high (0.75/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Aldeyra Therapeutics Inc is $4.6M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
On Aldeyra Therapeutics Inc, 2016-02-26 had a stock price of $3.73. If you invested back then, your return now would be a profit of $1.760 per share or 47.18%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.